Jasper Therapeutics, Inc. JSPR 深 滬
已收盤 07-02 16:00:00 美东时间
0.4283
-0.026
-5.76%
華盛通- 最 高0.4799
- 今 開0.46
- 成交量 21.77万股
- 最 低 0.4238
- 昨 收 0.4545
- 總市值 1199.66万
- 52周最高 3.53
- 市盈率 靜 --
- 換手率 0.78%
- 52周最低 0.3151
- 委 比 90.48%
- 總股本 2800.98万
- 歷史最高 188.80
- 量 比 0.33
- 振 幅 12.34%
- 歷史最低 0.3151
- 每 手 1
- 風險率 0.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jasper Therapeutics Received Notice Of Non-Compliance With Nasdaq Minimum Bid Requirements On June 3
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001788028/000121390026066782/ea0294010-8k_jasper.htm
06-10 04:10
Jasper Therapeutics shares are trading lower. The company announced its Board has decided to initiate a comprehensive review of strategic alternatives to maximize shareholder value.
Jasper Therapeutics shares are trading lower. The company announced its Board h...
06-02 03:50
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
TD Cowen Downgrades Jasper Therapeutics to Hold
TD Cowen analyst Yaron Werber downgrades Jasper Therapeutics (NASDAQ:JSPR) from Buy to Hold.
05-16 00:45
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3
RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Perform and lowers the price target from $4 to $3.
05-15 22:05
美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7
Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target from $12 to $7.
04-02 01:06
Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.64) by 50.31 percent. This is a 80.25 percent increase over losses of $(1.62) per share
03-31 04:53
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock rose 19.6% to $1.4 during Frid...
02-13 20:05
Jasper Therapeutics Reports Updated Clinical Data From BEACON Phase 1b/2a Study Of Subcutaneous Briquilimab In Adult Participants With CSU, As Well As From Open Label Extension Study In CSU And CIndU
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension
01-08 20:09
